Company
Fresenius Kabi
Fresenius Kabi has 54 drugs tracked on RxWires: 14 post-market, 19 approved, 13 in Phase 3, 1 in Phase 2, 1 in Phase 1/2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Volulyte | Post-Market | Burns |
| Intradialytic Parenteral Nutrition (IDPN) | Post-Market | Malnutrition |
| Hydroxyethylstarch 130/0.4 | Post-Market | Intraoperative Complications |
| Dipeptiven | Post-Market | Traumatic Brain Injury |
| Ketosteril® | Post-Market | Diabetic Nephropathy |
| balanced 6% hydroxyethylstarch 130/0.4 | Post-Market | Surgery, Colorectal |
| HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Post-Market | Hypotension |
| Glutamine | Post-Market | Malnourishment |
| Volulyte 6% | Post-Market | Hypovolaemia Due to Acute Blood Loss |
| Lactulose crystals 20 g | Post-Market | Diabetes Mellitus, Type 2 |
| SMOFlipid® (lipid injectable emulsion) | Post-Market | Malnutrition, Child |
| tetrastarch (Voluven) | Post-Market | Abdominal Hypertension |
| Lactated Ringer's Solution | Post-Market | Fluid Overload |
| Hydroxyethyl Starch 130/0.4 (Voluven) | Post-Market | Postoperative Complications |
| ADENOSINE | Approved | |
| LEVOFLOXACIN | Approved | |
| TERBUTALINE SULFATE | Approved | |
| DEXTROSE | Approved | |
| VINCRISTINE SULFATE | Approved | |
| POTASSIUM CHLORIDE | Approved | |
| FLUOROURACIL | Approved | |
| STERILE WATER | Approved | |
| SENSORCAINE MPF | Approved | |
| ACETAMINOPHEN | Approved | |
| SUMATRIPTAN SUCCINATE | Approved | |
| HALOPERIDOL | Approved | |
| PROTAMINE SULFATE | Approved | |
| STIMUFEND | Approved | |
| CARDIOPLEGIC SOLUTION | Approved | |
| CALREZDY | Approved | |
| PAMIDRONATE DISODIUM | Approved | |
| SODIUM BICARBONATE | Approved | |
| CIENBY | Approved | |
| L-Alanyl/L-Glutamine | Phase 3 | Cardiac Surgery |
| FKS518 | Phase 3 | Postmenopausal Osteoporosis |
| 6% hydroxyethyl starch 130/0.4 | Phase 3 | Hypovolemia |
| Soybean oil (Standard treatment) | Phase 3 | Total Parenteral Nutrition-induced Cholestasis |
| Propofol | Phase 3 | General Anesthesia |
| PA21 (Velphoro®) | Phase 3 | Hyperphosphatemia |
| Smoflipid 20% (investigational lipid for parenteral nutrition) | Phase 3 | Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days |
| SmofKabiven extra Nitrogen | Phase 3 | Nutrition Therapy |
| 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Phase 3 | Sepsis |
| Patiromer Powder for Oral Suspension (Part A) | Phase 3 | Hyperkalemia |
| 1: Hydroxyethyl starch 130/0.4, 6 % | Phase 3 | Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage |
| MSB11022 | Phase 3 | Psoriasis |
| SmofKabiven emulsion for infusion | Phase 3 | Parenteral Nutrition |
| Difelikefalin | Phase 2 | Pruritus |
| Nutrition counseling | Phase 1/2 | Head &Amp;Amp; Neck Squamous Cell Carcinoma |
| Amoxicillin | Phase 1 | Short Bowel Syndrome |
| Nanoxel (Paclitaxel Nanoparticle formulation ) | Phase 1 | Advanced Breast Cancer |
| Glucagon for Injection (Fresenius Kabi USA) | Phase 1 | Hypoglycemia |
| α-Keto Acid with restricted protein diet | Not Applicable | Renal Function Disorder |
| Combined cycle ergometry and bolus amino acid supplementation | Not Applicable | Critical Illness |
| Anemia Control Model (ACM) | Not Applicable | Anemia |
Latest
- Label updated: ACETAMINOPHEN
- Label updated: POTASSIUM CHLORIDE
- Label updated: DEXTROSE MONOHYDRATE
- Label updated: BUPIVACAINE HYDROCHLORIDE
- Boxed warning added: WATER
Follow Fresenius Kabi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.